Follicular rash during therapy with erlotinib (Tarceva)

J Dtsch Dermatol Ges. 2006 Oct;4(10):855-7. doi: 10.1111/j.1610-0387.2006.06088.x.
[Article in English, German]

Abstract

Erlotinib is a small-molecule tyrosine kinase inhibitor of the EGF receptor which has become an important oncological agent, used primarily in treating non-small-cell lung cancer. The most common side effects of this class of EGF receptor antagonists are cutaneous rashes. The severity of the skin rash seems to be correlated to clinical response and should be a motivating factor to continue therapy. We report a case of a patient who developed a follicular rash during therapy with erlotinib.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Erlotinib Hydrochloride
  • Facial Dermatoses / chemically induced*
  • Facial Dermatoses / pathology*
  • Folliculitis / chemically induced*
  • Folliculitis / pathology*
  • Humans
  • Lung Neoplasms / drug therapy
  • Male
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Pruritus / chemically induced*
  • Pruritus / diagnosis*
  • Quinazolines / adverse effects*
  • Quinazolines / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride